{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:37:42Z","timestamp":1769607462920,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.bbmt.2014.02.002","type":"journal-article","created":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T00:16:24Z","timestamp":1392077784000},"page":"717-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Peripheral Blood CD34+ Percentage at Hematological Recovery after Chemotherapy Is a Good Early Predictor of Harvest: A Single-Center Experience"],"prefix":"10.1016","volume":"20","author":[{"given":"Roberto","family":"Sorasio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Bonferroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Strola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Rapezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Marenchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Mordini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Celeghini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Borra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Ghiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gallamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.02.002_bib1","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1182\/blood-2011-06-318220","article-title":"How I treat patients who mobilize hematopoietic stem cells poorly","volume":"118","author":"To","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.002_bib2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of \u201cpoor mobilizer\u201d in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","article-title":"AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data","volume":"41","author":"Calandra","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib4","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.002_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/bmt.2010.54","article-title":"Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data","volume":"46","author":"Duarte","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbmt.2011.07.014","article-title":"Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma","volume":"18","author":"Attolico","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2014.02.002_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbmt.2013.11.003","article-title":"Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification","volume":"20","author":"Costa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bmt.2010.78","article-title":"Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib10","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2012.74","article-title":"Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization","volume":"47","author":"Chen","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/bmt.2011.133","article-title":"A\u00a0risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor","volume":"47","author":"Abhyankar","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/bmt.2011.217","article-title":"Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration","volume":"47","author":"Horwitz","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib13","first-page":"94","article-title":"Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding \u201con demand\u201d use of plerixafor","volume":"11","author":"Milone","year":"2013","journal-title":"Blood Transf"},{"key":"10.1016\/j.bbmt.2014.02.002_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/10428194.2013.802783","article-title":"Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor","volume":"55","author":"Farina","year":"2014","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2014.02.002_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.12606","article-title":"Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs","volume":"164","author":"Milone","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2014.02.002_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jca.21274","article-title":"A\u00a0retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly","volume":"28","author":"Hay","year":"2013","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.bbmt.2014.02.002_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-3148.1997.d01-75.x","article-title":"The kinetics of G-CSF mobilization of CD34+ cells in healthy people","volume":"7","author":"Stroncek","year":"1997","journal-title":"Transfus Med"},{"key":"10.1016\/j.bbmt.2014.02.002_bib18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bbmt.2011.10.002","article-title":"Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more\u00a0than 1,000 collections","volume":"18","author":"Gambell","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib20","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood.V72.6.2074.2074","article-title":"Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients","volume":"72","author":"D\u00fchrsen","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.002_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/(SICI)1097-0320(19980415)34:2<61::AID-CYTO1>3.0.CO;2-F","article-title":"Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering","volume":"34","author":"Keeney","year":"1998","journal-title":"Cytometry"},{"key":"10.1016\/j.bbmt.2014.02.002_bib22","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3109\/10428194.2011.578312","article-title":"Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late","volume":"52","author":"Basak","year":"2011","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2014.02.002_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0609.2010.01573.x","article-title":"Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience","volume":"86","author":"Jantunen","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2014.02.002_bib24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/bmt.2010.128","article-title":"The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF","volume":"46","author":"D'Addio","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.002_bib25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ajh.23499","article-title":"Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization","volume":"88","author":"Smith","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2014.02.002_bib26","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.002_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in\u00a0vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.002_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.beha.2011.12.001","article-title":"Primary CNS lymphoma","volume":"25","author":"Ferreri","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2014.02.002_bib29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bmt.1705862","article-title":"IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients","volume":"40","author":"Magagnoli","year":"2007","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:47:16Z","timestamp":1761058036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S1083879114000792"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.02.002","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral Blood CD34+ Percentage at Hematological Recovery after Chemotherapy Is a Good Early Predictor of Harvest: A Single-Center Experience","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}